MPO and transient ischemic attack: Studies have shown that the administration of melatonin immediately prior to transient cerebral ischemia or at the beginning of reperfusion results in a decrease in the cellular inflammatory response, edema, and neural cellular immune reactivity against NOS, COX2, and myeloperoxidase, and that these changes are effective in reducing and healing I/R damage in experimental animals [31,32].